Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PTAR1 is the alpha subunit of a newly characterized protein prenyltransferase, GGTase-III, which partners with the RabGGTB beta subunit to transfer geranylgeranyl groups specifically to substrates such as FBXL2 and Ykt6[2][4]. This modification is vital for anchoring these target proteins to cellular membranes, controlling their localization and turnover. PTAR1-mediated geranylgeranylation of FBXL2 influences membrane protein polyubiquitylation, while modification of Ykt6 is essential for Golgi membrane integration and SNARE complex formation, contributing to vesicular trafficking and maintenance of organellar structure[2]. PTAR1 resides primarily in the mitochondria but is also implicated in broader organelle functions[3]. Although no drugs currently target PTAR1 directly, the enzyme’s activity is linked to disease mechanisms including cancer and membrane homeostasis.
Drugs interacting with prenyltransferases typically act by inhibiting prenyl group transfer, disrupting membrane localization and downstream signaling of target substrates[1][2]. For GGTase inhibitors, the mechanism is blockade of geranylgeranylation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein prenyltransferase alpha subunit repeat containing 1 (PTAR1).